文献速递艾滋病与性传播感染结核与非结核分枝杆菌

HIV及结核/HIV合并感染儿童依非韦伦群体药代动力学:基因型指导给药的意义

Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

结果显示抗结核治疗对PK参数无显著影响,但体重、CYP2B6复合基因型和PK访视显著影响PK参数,模拟显示仅中间代谢型C12达标。

要点

  • 含利福平和异烟肼的抗结核治疗不影响儿童依非韦伦PK参数。
  • 体重、CYP2B6复合基因型和PK访视显著影响依非韦伦PK参数。
  • 模拟显示仅中间复合CYP2B6代谢型儿童C12达标。

核心结论

  • 含利福平和异烟肼的抗结核治疗不影响儿童依非韦伦PK参数。
  • 模型描述了完成结核治疗后依非韦伦自身诱导效应。
  • 仅按体重给药导致儿童药物暴露变异大,提出对慢和快复合CYP2B6代谢型调整剂量。

研究设计与样本

  • 中位年龄7岁,中位体重19kg。
  • 开始依非韦伦后4周采PK样本(PK1),合并结核/HIV患者完成结核治疗后4周重复采PK样本(PK2)。

主要发现

  • 用一室模型充分描述依非韦伦浓度随时间变化。
  • 体重、复合CYP2B6基因型和PK访视对PK参数有显著影响,结核治疗无显著影响。
  • 模拟显示仅中间复合CYP2B6代谢型儿童C12达标。

临床怎么用

  • 儿童依非韦伦剂量调整需考虑CYP2B6复合基因型而非仅体重。
  • 对慢和快复合CYP2B6代谢型儿童建议调整依非韦伦剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The current WHO weight-based dosing recommendations for efavirenz result in a wide variability of drug exposure in children. Our objectives are to characterize the effects of rifampicin- and isoniazid-containing anti-TB therapy and CYP2B6 activity on efavirenz concentrations in children, using non-linear mixed-effects modelling. METHODS: This is a pharmacokinetic (PK) substudy of a prospective study that examined the interactions between anti-TB therapy and efavirenz in HIV-infected children with and without TB. PK samples were obtained 4 weeks after starting efavirenz (PK1) and repeated 4 weeks after completing TB therapy (PK2) in TB/HIV coinfected patients. Drug concentrations were measured using LC-MS/MS. Composite CYP2B6 516/983/15582 genotype was determined. Population PK modelling was performed in Monolix. Simulations were performed to obtain the predicted mid-dose concentrations (C12). RESULTS: One hundred and five HIV-infected Ghanaian children (46 with TB/HIV) were included. The median age and weight were 7 years and 19 kg. The efavirenz concentrations over time were adequately described using a one-compartment model. Weight, composite CYP2B6 genotype and PK visit had a significant influence on the PK parameters, while TB therapy had no significant effect. Simulations showed adequate C12 for intermediate composite CYP2B6 metabolizers only. CONCLUSIONS: Our model showed that rifampicin- and isoniazid-containing anti-TB therapy does not influence efavirenz PK parameters. On the other hand, it describes the effect of efavirenz autoinduction after completing TB treatment. In addition, dosing efavirenz in children based only on weight results in a large variability in drug exposure. We propose dose adjustments for slow and extensive composite CYP2B6 metabolizers.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Alghamdi WA, Antwi S, Enimil A, et al. Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing. J Antimicrob Chemother. 2019. PMID: 31243456. doi:10.1093/jac/dkz238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。